{"id":740,"date":"2021-11-25T14:14:31","date_gmt":"2021-11-25T14:14:31","guid":{"rendered":"https:\/\/vicare.org.ar\/?p=2211"},"modified":"2021-11-25T14:14:31","modified_gmt":"2021-11-25T14:14:31","slug":"investigacion-sobre-el-cancer-de-vejiga","status":"publish","type":"post","link":"https:\/\/vicare.ar\/eng\/investigacion-sobre-el-cancer-de-vejiga\/","title":{"rendered":"Bladder cancer research"},"content":{"rendered":"<ul>\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2023\/cancer-vejiga-terapia-adyuvante-nivolumab\">Se observaron beneficios de largo plazo en las personas con c\u00e1ncer de vejiga de riesgo alto que recibieron inmunoterapia despu\u00e9s de la cirug\u00eda<\/a>Publicaci\u00f3n:&nbsp;14 de abril de 2023Los resultados actualizados de un estudio cl\u00ednico grande confirman que, para las personas con c\u00e1ncer de vejiga operable, recibir inmunoterapia despu\u00e9s de la cirug\u00eda es un tratamiento eficaz. En 2021, los resultados iniciales del mismo estudio llevaron a que la FDA aprobara el nivolumab (Opdivo) para este uso.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2020\/aprueba-fda-enfortumab-vedotina-cancer-vejiga\">Se aprueba el enfortumab vedotina para el c\u00e1ncer de vejiga recidivante<\/a>Publicaci\u00f3n:&nbsp;11 de marzo de 2020Se aprueba el enfortumab vedotina-ejfv (Padcev) para las personas con c\u00e1ncer de vejiga avanzado. La FDA otorg\u00f3 la aprobaci\u00f3n acelerada del medicamento para tratar c\u00e1nceres que progresaron a pesar de los tratamientos anteriores.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2019\/erdafitinib-cancer-avanzado-vejiga\">F\u00e1rmaco dirigido erdafitinib beneficia a algunos pacientes con c\u00e1ncer avanzado de vejiga<\/a>Publicaci\u00f3n:&nbsp;24 de septiembre de 2019Nuevos resultados de un estudio cl\u00ednico confirman que la terapia dirigida erdafitinib (Balversa) puede beneficiar a pacientes con c\u00e1ncer avanzado de vejiga cuyos tumores tienen una alteraci\u00f3n gen\u00e9tica en uno de los cuatro genes de FGFR.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2018\/vejiga-cancer-punto-de-control-inhibidor-modificacion\">La FDA modifica el uso aprobado de dos inhibidores de punto de control para c\u00e1ncer de vejiga<\/a>Publicaci\u00f3n:&nbsp;11 de octubre de 2018La FDA ha modificado los usos aprobados de los f\u00e1rmacos de inmunoterapia pembrolizumab (Keytruda) y atezolizumab (Tecentriq) para tratar la forma m\u00e1s com\u00fan de c\u00e1ncer de vejiga. La modificaci\u00f3n se basa en si los tumores de los pacientes tienen un biomarcador espec\u00edfico.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2017\/fda-nivolumab-vejiga\">FDA aprueba nivolumab para el c\u00e1ncer de vejiga<\/a>Publicaci\u00f3n:&nbsp;28 de junio de 2017La FDA ha aprobado nivolumab para el tratamiento de c\u00e1ncer de vejiga no resecable metast\u00e1tico o localmente avanzado que empeor\u00f3 despu\u00e9s de tratamiento con quimioterapia a base de platino.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2017\/aprobaciones-fda-puntodecontrol-vejiga\">FDA aprueba f\u00e1rmacos de inmunoterapia para pacientes con c\u00e1ncer de vejiga<\/a>Publicaci\u00f3n:&nbsp;30 de mayo de 2017La FDA ha aprobado cuatro f\u00e1rmacos de inmunoterapia\u2014avelumab, atezolizumab, durvalumab y pembrolizumab\u2014para el tratamiento de pacientes con c\u00e1ncer de vejiga. Todos los cuatro f\u00e1rmacos pertenecen a una clase de terapias de c\u00e1ncer conocidas como inhibidores de punto de control.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2016\/fda-atezolizumab-vejiga\">FDA aprueba nuevo f\u00e1rmaco de inmunoterapia para c\u00e1ncer de vejiga<\/a>Publicaci\u00f3n:&nbsp;24 de junio de 2016La FDA ha aprobado atezolizumab (Tecentriq\u00ae) para el tratamiento de algunos pacientes con carcinoma urotelial, el tipo m\u00e1s com\u00fan de c\u00e1ncer de vejiga.<\/li>\n<\/ul>\n\n\n\n<p>Fuente: https:\/\/www.cancer.gov\/espanol\/tipos\/vejiga\/investigacion<\/p>","protected":false},"excerpt":{"rendered":"<p>Fuente: https:\/\/www.cancer.gov\/espanol\/tipos\/vejiga\/investigacion<\/p>","protected":false},"author":1,"featured_media":741,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[7],"tags":[12,24,36,25],"_links":{"self":[{"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/posts\/740"}],"collection":[{"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/comments?post=740"}],"version-history":[{"count":0,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/posts\/740\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/media\/741"}],"wp:attachment":[{"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/media?parent=740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/categories?post=740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/tags?post=740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}